Clinical trials
Completed Observational Demyelinating Diseases trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
13 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2008 | 2 |
| 2010 | 2 |
| 2011 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 13 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Institute of Neurological Disorders and Stroke (NINDS) | 2 |
| Association de Recherche Bibliographique pour les Neurosciences | 1 |
| Dragonfly Research, LLC | 1 |
| EMD Serono | 1 |
| Heinrich-Heine University, Duesseldorf | 1 |
| Hospices Civils de Lyon | 1 |
| Merck KGaA, Darmstadt, Germany | 1 |
| The Hospital for Sick Children | 1 |
| The University of Texas Health Science Center, Houston | 1 |
| University of California, San Francisco | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Demyelinating Diseases | 13 |
| Multiple Sclerosis | 7 |
| Autoimmune Diseases | 4 |
| Immune System Diseases | 4 |
| Nervous System Diseases | 4 |
| Autoimmune Diseases of the Nervous System | 3 |
| Demyelinating Autoimmune Diseases, CNS | 2 |
| Multiple Sclerosis, Relapsing-Remitting | 2 |
| Pathologic Processes | 2 |
| COVID-19 | 1 |
Trials
Showing 1 to 13 of 13. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.